Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus Penpulimab in Advanced NSCLC
NCT05460481Phase 2Unknown
- Sponsor
- Hunan Cancer Hospital
- Start
- Jun 2022
- Primary completion
- Jun 2023
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib and penpulimab in non-small cell lung cancer (NSCLC), sponsored by Hunan Cancer Hospital. Primary endpoint: Objective Response Rate at 24 months. Status: unknown.
02
Drugs
anlotinibpenpulimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05460481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05460481.